---
schema_version: "secwatch.filing_event.v1"
accession: "0001576885-23-000008"
form_type: "8-K"
ticker: "ABOS"
cik: "0001576885"
company_name: "Acumen Pharmaceuticals, Inc."
filed_at: "2023-03-15T23:59:59+00:00"
generated_at: "2026-06-18T02:01:26.249270+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Acumen amends bylaws to adopt universal proxy rules and DGCL updates

## Summary
- Board adopted amended bylaws effective March 9, 2023, to comply with SEC Rule 14a-19 (universal proxy) and recent DGCL changes.
- Enhanced disclosure requirements for stockholder director nominations, including background info and proxy solicitation intent.
- Company will disregard nominations if stockholder fails to comply with Rule 14a-19 after providing notice.
- Stockholders soliciting proxies must use a proxy card other than white; white card reserved for Board use.
- Updated provisions on meeting adjournment procedures and stockholder list to reflect DGCL amendments.

## SEC filing metadata
- accession: 0001576885-23-000008
- form_type: 8-K
- ticker: ABOS
- cik: 0001576885
- company_name: Acumen Pharmaceuticals, Inc.
- filed_at: 2023-03-15T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576885/000157688523000008/0001576885-23-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576885/000157688523000008/abos-20230309.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001576885-23-000008
- JSON: https://secwatch.observer/filing/0001576885-23-000008.json
- Plain text: https://secwatch.observer/filing/0001576885-23-000008.txt

## Key facts
- Governance Changes
  Acumen Pharmaceuticals, Inc.: Adopted amended and restated bylaws including enhancements to stockholder nomination procedures and updates for universal proxy rules and DGCL changes (effective 2023-03-09).
  - Change: bylaw amendment
  - Effective: 2023-03-09
  source text: On March 9, 2023, in connection with the adoption of Rule 14a-19 (the “Universal Proxy Rules”) under the Securities Exchange Act of 1934, as amended, certain recent changes to the Delaware General Corporation Law (the “DGCL”), and a periodic review of the bylaws of Acumen Pharmaceuticals, Inc. (the “Company”), the Board of Directors of the Company (the “Board”) adopted amended and restated bylaws (the “Amended and Restated Bylaws”), effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576885/000157688523000008/0001576885-23-000008-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.